<DOC>
	<DOCNO>NCT00417144</DOCNO>
	<brief_summary>The purpose study compare pregnancy rate occurrence OHSS PCOS patient treat GnRH agonist GnRH antagonist protocol ovarian stimulation IVF cycle . Our hypothesis GnRH antagonist protocol reduces occurrence severity OHSS compare GnRH agonist protocol .</brief_summary>
	<brief_title>Comparison Between GnRH Agonist GnRH Antagonist Protocols Ovarian Stimulation PCOS Patients</brief_title>
	<detailed_description>Women polycystic ovarian syndrome ( PCOS ) represent group patient high risk develop ovarian hyperstimulation syndrome ( OHSS ) , iatrogenic complication ovarian stimulation IVF treatment . In contrast mild OHSS , severe OHSS life-threatening complication , characterize massive ovarian enlargement , ascites , pleural effusion , oliguria , haemoconcentration thromboembolic phenomenon . Currently , curative therapy OHSS available thus prevention consider effective “ treatment ” . Several measure adopt reduce occurrence syndrome , effective cycle cancellation withhold human chorionic gonadotropin ( hCG ) , seem critical factor development OHSS . COMPARISON : This study aim compare development severity OHSS , well ongoing pregnancy rate PCOS patient receive flexible GnRH antagonist ( Ganirelix ) protocol v long GnRH agonist ( Arvekap ) protocol ovarian stimulation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Clinical diagnosis PCOS ( presence oligoovulation/anovulation polycystic ovary ) Normal responder Poor responder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>OHSS</keyword>
	<keyword>PCOS</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>GnRH agonist</keyword>
</DOC>